Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Behcet's Disease Uveitis

In brief

The objective of this study is to assess the efficacy and safety of gevokizumab in treating Behcet's disease uveitis (BDU).

Key facts

Study ID

NCT02258867

Run by

XOMA (US) LLC

People needed

4

Starts

2014-11-01

Expected to finish

2015-11-01

Last updated by the study team

2015-12-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have characteristics of Behcet's disease consistent with International Criteria for Behcet's disease
• Have a documented history of active uveitis with or without retinal vasculitis within the past 12 months
• Best corrected visual acuity (BCVA) >= 20 ETDRS letters in both eyes at baseline
• Effective contraceptive measures

You may not qualify if…

• Infectious uveitis and masquerade syndromes
• End stage ocular disease
• History of allergic or anaphylactic reactions to monoclonal antibodies
• Active tuberculosis disease
• History of recurrent infection or predisposition to infection; active ocular infection
• Pregnant or nursing women
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Study site — Santa Ana, California, United States
• Study site — Chicago, Illinois, United States
• Study site — Ellsworth, Maine, United States
• Study site — Cambridge, Massachusetts, United States
• Study site — Royal Oak, Michigan, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Fargo, North Dakota, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.